<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/75C79916-E88B-43AF-AAC0-41353A5C0D6A"><gtr:id>75C79916-E88B-43AF-AAC0-41353A5C0D6A</gtr:id><gtr:name>F-Star Biotechnology Limited</gtr:name><gtr:address><gtr:line1>MONETA B280 , BABRAHAM RESEARCH CAMPUS</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75C79916-E88B-43AF-AAC0-41353A5C0D6A" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>75C79916-E88B-43AF-AAC0-41353A5C0D6A</gtr:id><gtr:name>F-Star Biotechnology Limited</gtr:name><gtr:address><gtr:line1>MONETA B280 , BABRAHAM RESEARCH CAMPUS</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>149994.0</gtr:offerGrant><gtr:projectCost>249449.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131059"><gtr:id>5A8EE846-CDE9-4291-8AB5-D3E5F729C072</gtr:id><gtr:title>DEVELOPMENT FEASIBILITY OF A NOVEL SUPERIOR HER2-SPECIFIC TARGETED DRUG CONJUGATE FOR CANCER THERAPY</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131059</gtr:grantReference><gtr:abstractText>F-star is an oncology-focused biopharmaceutical company and is applying its Modular Antibody Technology to the development of a pipeline of bispecific antibody products. F-star's modular approach is based on introducing an antigen binding site into the Fc fragment of an antibody. The resulting Fcabs can be used to rapidly generate a bispecific from any antibody. The relatively long serum half-life and potential for improved tissue penetration of these Fcabs suggests that they will be particularly well suited to an antibody drug conjugate (ADC) approach. F-star has generated an Fcab which binds potently to Her2 and has demonstrated promising efficacy in mouse xenograft models. In this project F-star will conjugate a cytotoxin to its anti-Her2 Fcab and evaluate the resulting antibody drug conjugate alongside current standard of care treatments in mouse xenograft models.</gtr:abstractText><gtr:fund><gtr:end>2014-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>149994</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131059</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>